Metabolic Association Between the Gut–Brain Axis in Autism Spectrum Disorders

  • María Andrea Delgado
  • Adriana Fochesato
  • Luis Isaías Juncos
  • Pascual Ángel Gargiulo
Chapter

Abstract

Autism spectrum disorder (ASD) is a severe, complex neurodevelopmental disorder, characterized by impairments in social interaction and communication with restricted and stereotyped behavior patterns. ASD symptoms result from a complex interaction between genetic and environment factors. Food intolerances, allergies, altered intestinal permeability (leaky gut), immune dysregulation, neuroinflammation and oxidative stress may trigger ASD symptoms. ASD patients have shown increased urinary levels of β-casomorphin and gliadorphin peptides produced by incomplete digestion of gluten proteins and milk casein. “Leaky gut” may facilitate the transport of these peptides into the central nervous system (CNS) inducing direct “opioid activity” and thus affecting neurotransmission. ASD patients on gluten and/or casein-free diet have shown improvement in most behavior and cognitive scores. Immune dysregulation leads to a neuroinflammatory response that correlates between immune dysfunction with behavioral and cognitive impairments in ASD patients. Genetic variants of the MET gene (7q31.2) are risk factors for ASD. The MET receptor participates in brain cortex and cerebellum development and in gastrointestinal and immunological functions. A high percentage of ASD children have shown non-celiac gluten sensitivity, an immune reaction against gluten in subjects not affected with celiac disease with prominent mucosal eosinophil infiltration and increased blood eosinophilia. ASD patients have shown alterations in brain anatomy involved in language and social interaction skills, correlating with specific aspects of ASD symptoms. ASD behavior results from abnormal interactions between the opioid system and various pathways together with anatomical alterations in the CNS. Individualized diagnosis and prognostic predictions should provide effective personalized therapies in ASD patients.

Keywords

Autism spectrum disorders Opioid peptides Leaky gut Genetics Immune dysregulation 

References

  1. 1.
    Lord C, Risi S, Lambrecht L, Cook Jr EH, Leventhal BL, DiLavore PC, Pickles A, Rutter M. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30(3):205–23.PubMedCrossRefGoogle Scholar
  2. 2.
    Christensen DL, Baio J, Van Naarden BK, Bilder D, Charles J, Constantino JN, Daniels J, Durkin MS, Fitzgerald RT, Kurzius-Spencer M, Lee LC, Pettygrove S, Robinson C, Schulz E, Wells C, Wingate MS, Zahorodny W, Yeargin-Allsopp M. Centers for disease control and prevention (CDC). Prevalence and characteristics of autism spectrum disorder among children aged 8 years-Autism and Developmental isabilities onitoring Network, 11 sites, United States, 2012. MMWR Surveill Summ. 2016;65(3):1–23.PubMedCrossRefGoogle Scholar
  3. 3.
    Volkmar F, Chawarska K, Klin A. Autism in infancy and early childhood. Annu Rev Psychol. 2005;56:315–36.PubMedCrossRefGoogle Scholar
  4. 4.
    Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M. Autism as a strongly genetic disorder: evidence from a British twin study. Psychol Med. 1995;25:63–77.PubMedCrossRefGoogle Scholar
  5. 5.
    Grafodatskaya D, Chung B, Szatmari P, Weksberg R. Autism spectrum disorders and epigenetics. J Am Acad Child Adolesc Psychiatry. 2010;49:794–809.PubMedCrossRefGoogle Scholar
  6. 6.
    Cade R, Private FM, Rowland N, Sun Z, Zele V, Wagemaker H, Edelstein C. Autism and schizophrenia: intestinal disorders. Nutr Neurosci. 2000;3:57–72.PubMedCrossRefGoogle Scholar
  7. 7.
    Molloy CA, Morrow AL, Meinzen-Derr J, Schleifer K, Dienger K, Manning-Courtney P, Altaye M, Wills-Karp M. Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol. 2006;172(1):198–205.PubMedCrossRefGoogle Scholar
  8. 8.
    Morgan JT, Chana G, Pardo CA, Achim C, Semendeferi K, Buckwalter J, Courchesne E, Everall IP. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry. 2010;68(4):368–76.PubMedCrossRefGoogle Scholar
  9. 9.
    Williams BL, Hornig M, Parekh T, Lipkin WI. Application of novel PCR based methods for detection, quantitation, and phylogenetic characterization of Sutterella species in intestinal biopsy samples from children with autism and gastrointestinal disturbances. MBio. 2012;3(1):e00261–11.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Chauhan A, Audhya T, Chauhan V. Brain region-specific glutathione redox imbalance in autism. Neurochem Res. 2012;37(8):1681–9.Google Scholar
  11. 11.
    Pellicano E. Do autistic symptoms persist across time? Evidence of substantial change in symptomatology over a 3-year period in cognitively able children with autism. Am J Intellect Dev Disabil. 2012;17(2):156–66.CrossRefGoogle Scholar
  12. 12.
    Fein D, Barton M, Eigsti IM, Kelley E, Naigles L, Schultz RT, Stevens M, Helt M, Orinstein A, Rosenthal M, Troyb E, Tyson K. Optimal outcome in individuals with a history of autism. J Child Psychol Psychiatry. 2013;54(2):195–205.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Eriksson MA, Westerlund J, Hedvall Å, Åmark P, Gillberg C, Fernell E. Medical conditions affect the outcome of early intervention in preschool children with autism spectrum disorders. Eur Child Adolesc Psychiatry. 2013;22(1):23–33.Google Scholar
  14. 14.
    Dohan FC. Cereals and schizophrenia data and hypothesis. Acta Psychiatr Scand. 1966;42:125–52.PubMedCrossRefGoogle Scholar
  15. 15.
    Reichelt KL, Hole K, Hamberger A, Saelid G, Edmminson PD, Braestrup CB, Lingjaerde O, Ledall P, Orbeck H. Biological active peptide containing fractions in schizophrenia and childhood autism. Adv Biochem Psychopharmacol. 1981;28:627–43.PubMedGoogle Scholar
  16. 16.
    Travé Rodriguez AL, Barreiro Marin P, Gálvez Borrero IM, del Olmo R-NF, Díaz ÁA. Association between autism and schizophrenia. J Nerv Ment Dis. 1994;182(8):478–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Gardner MLG. Absorption of intact proteins and peptides. In: Johnson LR, editor. Physiology of the gastro-intestinal tract. New York: Raven Press; 1994. p. 1795–820.Google Scholar
  18. 18.
    D’Eufemia P, Celli M, Finocchiaro R, Pacifico L, Viozzi L, Zaccagnini M, Cardi E, Giardini O. Abnormal intestinal permeability in children with autism. Acta Paediatr. 1996;85:1076–9.PubMedCrossRefGoogle Scholar
  19. 19.
    de Magistris L, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, Carteni M, De Rosa M, Francavilla R, Riegler G, Militerni R, Bravaccio C. Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives. J Pediatr Gastroenterol Nutr. 2010;51(4):418–24.PubMedCrossRefGoogle Scholar
  20. 20.
    Goodwin MS, Cowen MA, Goodwin TC. Malabsorption and cerebral dysfunction. A multivariate and comparative study of autistic children. J Autism Child Schizophr. 1971;1:48–62.PubMedCrossRefGoogle Scholar
  21. 21.
    Coleman M. Calcium studies and their relationship to coeliac disease in autistic patients. In: Colema M, editor. The autistic syndromes. Amsterdam: North Holland Publishing Corp; 1976. p. 197–205.Google Scholar
  22. 22.
    Buie T, Fuchs 3rd GJ, Furuta GT, Kooros K, Levy J, Lewis JD, Wershil BK, Winter H. Recommendations for evaluation and treatment of common gastrointestinal problems in children with ASDs. Pediatrics. 2010;125(Suppl 1):S19–29.PubMedCrossRefGoogle Scholar
  23. 23.
    Gorrindo P, Williams KC, Lee EB, Walker LS, McGrew SG, Levitt P. Gastrointestinal dysfunction in autism: parental report, clinical evaluation, and associated factors. Autism Res. 2012;5(2):101–8.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    McElhanon BO, McCracken C, Karpen S, Sharp WG. Gastrointestinal symptoms in autism spectrum disorder: a meta-analysis. Pediatrics. 2014;133(5):​872–83.PubMedCrossRefGoogle Scholar
  25. 25.
    Kanner L. Follow-up study of eleven autistic children originally reported in 1943. J Autism Child Schizophr. 1971;1(2):119–45.PubMedCrossRefGoogle Scholar
  26. 26.
    Adams JB, Audhya T, McDonough-Means S, Rubin RA, Quig D, Geis E, Gehn E, Loresto M, Mitchell J, Atwood S, Barnhouse S, Lee W. Effect of a vitamin/mineral supplement on children and adults with autism. BMC Pediatr. 2011;11:111.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Sun Z, Cade JR, Fregly MJ, Privette RM. β-Casomorphin induces fos-like immunoreactivity in discrete brain regions relevant to schizophrenia and autism. Autism. 1999;3(1):67–83.CrossRefGoogle Scholar
  28. 28.
    Sun Z, Cade R. A peptide found in schizophrenia and autism causes behavioral changes in rats. Autism. 1999;3(1):85–95.CrossRefGoogle Scholar
  29. 29.
    Panksepp J. A neurochemical theory of autism. Trends Neurosci. 1979;2:174–7.CrossRefGoogle Scholar
  30. 30.
    Reichelt KL, Knivsberg AM, Nodland M, Lind G. Nature and consequence of hyperpeptiduria and bovine casomorphine found in autistic Syndromes. Brain Dysfunction. 1994;7:71–85.Google Scholar
  31. 31.
    Reichelt KL, Knivsberg AM. Can the pathophysiology of autism be explained by the nature of the discovered urine peptides? Nutr Neurosci. 2003;6:19–28.PubMedCrossRefGoogle Scholar
  32. 32.
    Reichelt KL, Tveiten D, Knivsberg AM, Brønstad G. Peptides: role in autism with emphasis on exorphins. Microb Ecol Health Dis. 2012;24:23.Google Scholar
  33. 33.
    Millward C, Ferriter M, Calver S, Connell-Jones G. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev. 2008;16(2):​CD003498.Google Scholar
  34. 34.
    Reichelt KL, Ekrem J, Scott H. Gluten, milk proteins and autism: dietary intervention effects on behavior and peptide secretion. J Appl Nutr. 1990;42(1):​1–11.Google Scholar
  35. 35.
    Lucarelli S, Frediani T, Zingoni AM, Ferruzzi F, Giardini O, Quintieri F, Barbato M, D’Eufemia P, Cardi E. Food allergy and infantile autism. Panminerva Med. 1995;37(3):137–41.PubMedGoogle Scholar
  36. 36.
    Whiteley P, Rodgersa J. Gluten-free diet as an intervention for autism and associated spectrum disorders: preliminary findings. Autism. 1999;3(1):45.CrossRefGoogle Scholar
  37. 37.
    Whiteley P, Shattock P. Biochemical aspects in autism spectrum disorders: updating the opioid-excess theory and presenting new opportunities for biomedical intervention. Expert Opin Ther Targets. 2002;6(2):175–83.PubMedCrossRefGoogle Scholar
  38. 38.
    Knivsberg AM, Reichelt KL, Høien T, Nødland M. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci. 2002;5(4):251–61.PubMedCrossRefGoogle Scholar
  39. 39.
    Pedersen L, Parlar S, Kvist K, Whiteley P, Shattock P. Data mining the ScanBrit study of a gluten- and casein-free dietary intervention for children with autism spectrum disorders: behavioural and psychometric measures of dietary response. Nutr Neurosci. 2014;17(5):207–13.PubMedCrossRefGoogle Scholar
  40. 40.
    Alarcón M, Abrahams BS, Stone JL, Duvall JA, Perederiy JV, Bomar JM, Sebat J, Wigler M, Martin CL, Ledbetter DH, Nelson SF, Cantor RM, Geschwind DH. Linkage, association, and gene-expression analyses identify CNTNAP2 as an autism-susceptibility gene. Am J Hum Genet. 2008;82(1):150–9.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Clement JP, Aceti M, Creson TK, Ozkan ED, Shi Y, Reish NJ, Almonte AG, Miller BH, Wiltgen BJ, Miller CA, Xu X, Rumbaugh G. Pathogenic SYNGAP1 mutations impair cognitive development by disrupting maturation of dendritic spine synapses. Cell. 2012;151(4):709–23.PubMedPubMedCentralCrossRefGoogle Scholar
  42. 42.
    Durand CM, Betancur C, Boeckers TM, Bockmann J, Chaste P, Fauchereau F, Nygren G, Rastam M, Gillberg IC, Anckarsäter H, Sponheim E, Goubran-Botros H, Delorme R, Chabane N, Mouren-Simeoni MC, de Mas P, Bieth E, Rogé B, Héron D, Burglen L, Gillberg C, Leboyer M, Bourgeron T. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders. Nat Genet. 2007;39(1):25–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Peñagarikano O, Abrahams BS, Herman EI, Winden KD, Gdalyahu A, Dong H, Sonnenblick LI, Gruver R, Almajano J, Bragin A, Golshani P, Trachtenberg JT, Peles E, Geschwind DH. Absence of CNTNAP2 leads to epilepsy, neuronal migration abnormalities, and core autism-related deficits. Cell. 2011;147(1):235–46.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Piggot J, Shirinyan D, Shemmassian S, Vazirian S, Alarcón M. Neural systems approaches to the neurogenetics of autism spectrum disorders. Neuroscience. 2009;164(1):247–56.PubMedCrossRefGoogle Scholar
  45. 45.
    Tabuchi K, Blundell J, Etherton MR, Hammer RE, Liu X, Powell CM, Südhof TC. A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science. 2007;318(5847):​71–6.PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Yashiro K, Riday TT, Condon KH, Roberts AC, Bernardo DR, Prakash R, Weinberg RJ, Ehlers MD, Philpot BD. Ube3a is required for experience-dependent maturation of the neocortex. Nat Neurosci. 2009;12(6):777–83.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Ebert DH, Greenberg ME. Activity-dependent neuronal signalling and autism spectrum disorder. Nature. 2013;493(7432):327–37.PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    Rubenstein JL, Merzenich MM. Model of autism: increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2003;2(5):255–67.PubMedCrossRefGoogle Scholar
  49. 49.
    Bradke F, Dotti CG. Establishment of neuronal polarity: lessons from cultured hippocampal neurons. Curr Opin Neurobiol. 2000;10(5):574–81.PubMedCrossRefGoogle Scholar
  50. 50.
    Mueller BK. Growth cone guidance: first steps towards a deeper understanding. Annu Rev Neurosci. 1999;22:351–88.PubMedCrossRefGoogle Scholar
  51. 51.
    Qui S, Aldinger KA, Levitt P. Modeling of autism genetic variations in mice: focusing on synaptic and microcircuit dysfunctions. Dev Neurosci. 2012;​34(2–3):88–100.Google Scholar
  52. 52.
    IMGSAC. A full genome screen for autism with evidence for linkage to a region on chromosome 7q. International molecular genetic study of autism consortium. Hum Mol Genet. 1998;7(3):571–8.CrossRefGoogle Scholar
  53. 53.
    IMGSAC. Further characterization of the autism susceptibility locus AUTS1 on chromosome 7q. Hum Mol Genet. 2001;10(9):973–82.CrossRefGoogle Scholar
  54. 54.
    Zhang H, Liu X, Zhang C, Mundo E, Macciardi F, Grayson DR, Guidotti AR, Holden JJ. Reelin gene alleles and susceptibility to autism spectrum disorders. Mol Psychiatry. 2002;7:1012–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Yonan AL, Alarcón M, Cheng R, Magnusson PKE, Spence SJ, Palmer AA, Grunn A, Juo SHH, Terwilliger JD, Liu J, Cantor RM, Geschwind DH, Gilliam TC. A genomewide screen of 345 families for autism-susceptibility loci. Am J Hum Genet. 2003;73(4):886–97.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    Persico AM, Napolioni V. Autism genetics. Behav Brain Res. 2013;15:95–112.CrossRefGoogle Scholar
  57. 57.
    Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, Vande Woude GF. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311(5981):​29–33.PubMedCrossRefGoogle Scholar
  58. 58.
    Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli A, Ponzetto C, Narsimhan RP, Hartmann G, Zarnegar R, Michalopoulos GK, Birchmeierl W, Comoglio PM. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J. 1991;10(10):2867–78.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Peng Y, Huentelman M, Smith C, Qiu S. MET receptor tyrosine kinase as an autism genetic risk factor. Int Rev Neurobiol. 2013;113:135–65.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Campbell DB, Buie TM, Winter H, Bauman M, Sutcliffe JS, Perrin JM, Levitt P. Distinct genetic risk based on association of MET in families with co-occurring autism and gastrointestinal conditions. Pediatrics. 2009;123(3):1018–24.PubMedCrossRefGoogle Scholar
  61. 61.
    Campbell DB. When linkage signal for autism MET candidate gene. Eur J Hum Genet. 2009;17(6):​699–700.PubMedCrossRefGoogle Scholar
  62. 62.
    Jackson PB, Boccuto L, Skinner C, Collins JS, Neri G, Gurrieri F, Schwartz CE. Further evidence that the rs1858830 C variant in the promoter region of the MET gene is associated with autistic disorder. Autism Res. 2009;2(4):232–6.PubMedCrossRefGoogle Scholar
  63. 63.
    Sousa I, Clark TG, Toma C, Kobayashi K, Choma M, Holt R, Sykes NH, Lamb JA, Bailey AJ, Battaglia A, Maestrini E, Monaco AP. MET and autism susceptibility: family and case-control studies. Eur J Hum Genet. 2009;17(6):749–58.PubMedCrossRefGoogle Scholar
  64. 64.
    Thanseem I, Nakamura K, Miyachi T, Toyota T, Yamada S, Tsujii M, Tsuchiya KJ, Anitha A, Iwayama Y, Yamada K, Hattori E, Matsuzaki H, Matsumoto K, Iwata Y, Suzuki K, Suda S, Kawai M, Sugihara G, Takebayashi K, Takei N, Ichikawa H, Sugiyama T, Yoshikawa T, Mori N. Further evidence for the role of MET in autism susceptibility. Neurosci Res. 2010;68(2):137–41.PubMedCrossRefGoogle Scholar
  65. 65.
    Campbell DB, D’Oronzio R, Garbett K, Ebert PJ, Mirnics K, Levitt P. Persico. Disruption of cerebral cortex MET signaling in autism spectrum disorder. AM. Ann Neurol. 2007;62(3):243–50.PubMedCrossRefGoogle Scholar
  66. 66.
    Birchmeier C, Gherardi E. Developmental roles of HGF/SF and its receptor, the c-Met tyrosine kinase. Trends Cell Biol. 1998;8:404–10.PubMedCrossRefGoogle Scholar
  67. 67.
    Yang XM, Park M. Expression of the MET/hepatocyte growth factor/scatter factor receptor and its ligand during differentiation of murine P19 embryonal carcinoma cells. Dev Biol. 1993;157:308–20.PubMedCrossRefGoogle Scholar
  68. 68.
    Leraci A, Forni PE, Ponzetto C. Viable hypomorphic signaling mutant of the Met receptor reveals a role for hepatocyte growth factor in postnatal cerebellar development. Proc Natl Acad Sci U S A. 2002;99:​15200–5.CrossRefGoogle Scholar
  69. 69.
    Judson MC, Bergman MY, Campbell DB, Eagleson KL, Levitt P. Dynamic gene and protein expression patterns of the autism-associated met receptor tyrosine kinase in the developing mouse forebrain. J Comp Neurol. 2009;513(5):511–31.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Judson MC, Eagleson KL, Levitt P. A new synaptic player leading to autism risk: met receptor tyrosine kinase. J Neurodev Disord. 2011;3(3):282–92.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Beilmann M, Odenthal M, Jung W, Vande Woude GF, Dienes HP, Schirmacher P. Neoexpression of the c-met/hepatocyte growth factor-scatter factor receptor gene in activated monocytes. Blood. 1997;90(11):​4450–8.PubMedGoogle Scholar
  72. 72.
    Tahara Y, Ido A, Yamamoto S, Miyata Y, Uto H, Hori T, Hayashi K, Tsubouchi H. Hepatocyte growth factor facilitates colonic mucosal repair in experimental ulcerative colitis in rats. J Pharmacol Exp Ther. 2003;307(1):146–15.PubMedCrossRefGoogle Scholar
  73. 73.
    Ido A, Numata M, Kodama M, Tsubouchi H. Mucosal repair and growth factors: recombinant human hepatocyte growth factor as an innovative therapy for inflammatory bowel disease. J Gastroenterol. 2005;40(10):925–31.PubMedCrossRefGoogle Scholar
  74. 74.
    Okunishi K, Dohi M, Nakagome K, Tanaka R, Mizuno S, Matsumoto K, Miyazaki J, Nakamura T, Yamamoto K. A novel role of hepatocyte growth factor as an immune regulator through suppressing dendritic cell function. J Immunol. 2005;175(7):​4745–53.PubMedCrossRefGoogle Scholar
  75. 75.
    Rudie JD, Hernandez LM, Brown JA, Beck-Pancer D, Colich NL, Gorrindo P, Thompson PM, Geschwind DH, Bookheimer SY, Levitt P, Dapretto M. Autism-associated promoter variant in MET impacts functional and structural brain networks. Neuron. 2012;75(5):904–15.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Campbell DB, Sutcliffe JS, Ebert PJ, Militerni R, Bravaccio C, Trillo S, Elia M, Schneider C, Melmed R, Sacco R, Persico AM, Levitt P. A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci U S A. 2006;​103(45):16834–9.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Quigley EM, Hurley D. Autism and the gastrointestinal tract. Am J Gastroenterol. 2000;95(9):2154–6.PubMedCrossRefGoogle Scholar
  78. 78.
    Levy SE, Souders MC, Ittenbach RF, Giarelli E, Mulberg AE, Pinto-Martin JA. Relationship of dietary intake to gastrointestinal symptoms in children with autistic spectrum disorders. Biol Psychiatry. 2007;61(4):492–7.PubMedCrossRefGoogle Scholar
  79. 79.
    Heuer L, Ashwood P, Schauer J, Goines P, Krakowiak P, Hertz-Picciotto I, Hansen R, Croen LA, Pessah IN, Van de Water J. Reduced levels of immunoglobulin in children with autism correlates with behavioral symptoms. Autism Res. 2008;1(5):275–83.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Enstrom A, Krakowiak P, Onore C, Pessah IN, Hertz-Picciotto I, Hansen RL, Van de Water JA, Ashwood P. Increased IgG4 levels in children with autism disorder. Brain Behav Immun. 2009;23(3):​389–95.PubMedCrossRefGoogle Scholar
  81. 81.
    Ashwood P, Krakowiak P, Hertz-Picciotto I, Hansen R, Pessah I, Van de Water J. Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain, Behav Immu. 2011;25(1):40–5.CrossRefGoogle Scholar
  82. 82.
    Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, Ji L, Brown T, Malik M. Elevated immune response in the brain of autistic patients. J Neuroimmunol. 2009;207(1):111–6.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Wei H, Zou H, Sheikh AM, Malik M, Dobkin C, Brown WT, Li X. IL-6 is increased in the cerebellum of autistic brain and alters neural cell adhesion, migration and synaptic formation. J Neuroinflammation. 2011;8(1):52.PubMedPubMedCentralCrossRefGoogle Scholar
  84. 84.
    Gupta S, Ellis SE, Ashar FN, Moes A, Bader JS, Zhan J, West AB, Arking DE. Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nat Commun. 2014;5:5748.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Boris M, Kaiser CC, Goldblatt A, Elice MW, Edelson SM, Adams JB, Feinstein DL. Effect of pioglitazone treatment on behavioral symptoms in autistic children. J Neuroinflammation. 2007;4:3.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Sharma A, Gokulchandran N, Chopra G, Kulkarni P, Lohia M, Badhe P, Jacob VC. Administration of autologous bone marrow-derived mononuclear cells in children with incurable neurological disorders and injury is safe and improves their quality of life. Cell Transplant. 2012;21(Supplement 1):S79–90.PubMedCrossRefGoogle Scholar
  87. 87.
    Schmitt J, Romanos M, Pfennig A, Leopold K, Meurer M. Psychiatric comorbidity in adult eczema. Br J Dermatol. 2009;161(4):878–83.PubMedCrossRefGoogle Scholar
  88. 88.
    Kohane IS, McMurry A, Weber G, MacFadden D, Rappaport L, Kunkel L, Bickel J, Wattanasin N, Spence S, Murphy S, Churchill S. The co-morbidity burden of children and young adults with autism spectrum disorders. PLoS One. 2012;7(4):e33224.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Fasmer OB, Riise T, Eagan TM, Lund A, Dilsaver SC, Hundal O, Oedegaard KJ. Comorbidity of asthma with ADHD. J Atten Disord. 2011;15(7):​564–71.PubMedCrossRefGoogle Scholar
  90. 90.
    Millman M, Campbell MB, Wright KL, Johnston A. Allergy and learning disabilities in children. Ann Allergy. 1976;36(3):149–60.PubMedGoogle Scholar
  91. 91.
    Price CE, Rona RJ, Chinn S. Associations of excessive irritability with common illnesses and food intolerance. Paediatr Perinat Epidemiol. 1990;4(2):​156–60.PubMedCrossRefGoogle Scholar
  92. 92.
    Angelidou A, Alysandratos KD, Asadi S, Zhang B, Francis K, Vasiadi M, Kalogeromitros D, Theoharides TC. Brief report: “allergic symptoms” in children with autism spectrum disorders. More than meets the eye? J Autism Dev Disord. 2011;41(11):1579–85.PubMedCrossRefGoogle Scholar
  93. 93.
    Theoharides TC, Enakuaa S, Sismanopoulos N, Asadi S, Papadimas EC, Angelidou A, Alysandratos KD. Contribution of stress to asthma worsening through mast cell activation. Ann Allergy Asthma Immunol. 2012;109(1):14–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Scaccianoce S, Lombardo K, Nicolai R, Affricano D, Angelucci L. Studies on the involvement of histamine in the hypothalamic–pituitary–adrenal axis activation induced by nerve growth factor. Life Sci. 2000;67(26):3143–52.PubMedCrossRefGoogle Scholar
  95. 95.
    Kalogeromitros D, Syrigou EK, Makris M, Kempuraj D, Stavrianeas NG, Vasiadi M, Theoharides TC. Nasal provocation of patients with allergic rhinitis and the hypothalamic–pituitary–adrenal axis. Ann Allergy Asthma Immunol. 2007;98(3):269–73.PubMedCrossRefGoogle Scholar
  96. 96.
    Liezmann C, Klapp B, Peters EM. Stress, atopy and allergy: a re-evaluation from a psychoneuroimmunologic persepective. Dermatoendocrinol. 2011;3(1):​37–40.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Jyonouchi H. Autism spectrum disorders and allergy: observation from a pediatric allergy/immunology clinic. Expert Rev Clin Immunol. 2010;6(3):​397–411.PubMedCrossRefGoogle Scholar
  98. 98.
    Catassi C, Bai JC, Bonaz B, Bouma G, Calabrò A, Carroccio A, Castillejo G, Ciacci C, Cristofori F, Dolinsek J, Francavilla R, Elli L, Green P, Holtmeier W, Koehler P, Koletzko S, Meinhold C, Sanders D, Schumann M, Schuppan D, Ullrich R, Vécsei A, Volta U, Zevallos V, Sapone A, Fasano A. Non-celiac gluten sensitivity: the new frontier of gluten-related disorders. Nutrients. 2013;5(10):3839–53.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Fasano A, Sapone A, Zevallos V, Schuppan D. Nonceliac gluten sensitivity. Gastroenterology. 2015;148(6):1195–204.PubMedCrossRefGoogle Scholar
  100. 100.
    Sapone A, Bai JC, Ciacci C, Dolinsek J, Green PH, Hadjivassiliou M, Kaukinen K, Rostami K, Sanders DS, Schumann M, Ullrich R, Villalta D, Volta U, Catassi C, Fasano A. Spectrum of gluten-related disorders: consensus on new nomenclature and classification. BMC Med. 2012;10:13.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Sandler RH, Finegold SM, Bolte ER, Buchanan CP, Maxwell AP, Väisänen ML, Nelson MN, Wexler HM. Short-term benefit from oral vancomycin treatment of regressive-onset autism. J Child Neurol. 2000;15(7):429–35.PubMedCrossRefGoogle Scholar
  102. 102.
    Schieve LA, Gonzalez V, Boulet SL, Visser SN, Rice CE, Van Naarden BK, Boyle CA. Concurrent medical conditions and health care use and needs among children with learning and behavioral developmental disabilities, National Health Interview Survey, 2006-2010. Res Dev Disabil. 2011;33(2):467–76.PubMedCrossRefGoogle Scholar
  103. 103.
    Carroccio A, Mansueto P, Iacono G, Soresi M, D’Alcamo A, Cavataio F, Brusca I, Florena AM, Ambrosiano G, Seidita A, Pirrone G, Rini GB. Non-celiac wheat sensitivity diagnosed by double-blind placebo-controlled challenge: exploring a new clinical entity. Am J Gastroenterol. 2012;107(12):​1898–906.PubMedCrossRefGoogle Scholar
  104. 104.
    Ashwood P, Anthony A, Pellicer AA, Torrente F, Walker-Smith JA, Wakefield AJ. Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. J ClinImmunol. 2003;23(6):504–17.Google Scholar
  105. 105.
    Chen B, Girgis S, El-Matary W. Childhood autism and eosinophilic colitis. Digestion. 2010;81(2):​127–9.PubMedCrossRefGoogle Scholar
  106. 106.
    Courchesne E, Campbell K, Solso S. Brain growth across the life span in autism: age-specific changes in anatomical pathology. Brain Res. 2011;1380:​138–45.PubMedCrossRefGoogle Scholar
  107. 107.
    Courchesne E, Pierce K, Schumann CM, Redcay E, Buckwalter JA, Kennedy DP, Morgan J. Mapping early brain development in autism. Neuron. 2007;56(2):399–413.PubMedCrossRefGoogle Scholar
  108. 108.
    Amaral DG, Schumann CM, Nordahl CW. Neuroanatomy of autism. Trends Neurosci. 2008;31(3):137–45.PubMedCrossRefGoogle Scholar
  109. 109.
    Catani M, Dell’Acqua F, Budisavljevic S, Howells H, Thiebaut de Schotten M, Froudist-Walsh S, D’Anna L, Thompson A, Sandrone S, Bullmore ET, Suckling J, Baron-Cohen S, Lombardo MV, Wheelwright SJ, Chakrabarti B, Lai MC, Ruigrok AN, Leemans A, Ecker C, Consortium MA, Craig MC, Murphy DG. Frontal networks in adults with autism spectrum disorder. Brain. 2016;139(Pt 2):​616–30.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Zioudrou C, Streaty RA, Klee WA. Opioid peptides derived from food proteins The exorphins. J Biol Chem. 1979;254(7):2446–9.PubMedGoogle Scholar
  111. 111.
    Huebner FR, Lieberman KW, Rubino RP, Wall JS. Demonstration of high opioid-like activity in isolated peptides from wheat gluten hydrolysates. Peptides. 1984;5(6):1139–47.PubMedCrossRefGoogle Scholar
  112. 112.
    van Elst LT, Maier S, Fangmeier T, Endres D, Mueller GT, Nickel K, Ebert D, Lange T, Hennig J, Biscaldi M, Riedel A, Perlov E. Magnetic resonance spectroscopy comparing adults with high functioning autism and above average IQ. Mol Psychiatry. 2014;19(12):1251.PubMedCrossRefGoogle Scholar
  113. 113.
    Siggins GR, Henriksen SJ, Chavkin C, Gruol D. Opioid peptides and epileptogenesis in the limbic system: cellular mechanisms. Adv Neurol. 1986;​44:501–12.PubMedGoogle Scholar
  114. 114.
    Wagner R, DeLeo JA, Coombs DW, Willenbring S, Fromm C. Spinal dynorphin immunoreactivity increases bilaterally in a neuropathic pain model. Brain Res. 1993;629(2):323–6.PubMedCrossRefGoogle Scholar
  115. 115.
    Simmons ML, Chavkin C. Endogenous opioid regulation of hippocampal function. Int Rev Neurobiol. 1996;39:145–96.PubMedCrossRefGoogle Scholar
  116. 116.
    Henriksen G, Willoch F. Imaging of opioid receptors in the central nervous system. Brain. 2008;131(Pt 5):1171–96.PubMedCrossRefGoogle Scholar
  117. 117.
    Zagon IS, Gibo DM, McLaughlin PJ. Adult and developing human cerebella exhibit different profiles of opioid binding sites. Brain Res. 1990;523:62–8.PubMedCrossRefGoogle Scholar
  118. 118.
    Zagon IS, McLaughlin PJ. Opioid growth factor receptor in the developing nervous system: laboratory findings. In: Zagon IS, McLaughlin PJ, editors. Receptors and the developing nervous system, Growth Factors and Hormones, vol. L. London: Chapman and Hall; 1993. p. 39–62.CrossRefGoogle Scholar
  119. 119.
    Froehlich JC. Opioid peptides. Alcohol Health Res World. 1997;21(2):132–6.PubMedGoogle Scholar
  120. 120.
    Teschemacher H. Opioid receptor ligands derived from food proteins. Curr Pharm Des. 2003;9(16):​1331–44.PubMedCrossRefGoogle Scholar
  121. 121.
    Doty RW. Schizophrenia: a disease of interhemispheric processes at forebrain and brainstem levels? Behav Brain Res. 1989;34(1–2):1–33.PubMedCrossRefGoogle Scholar
  122. 122.
    Sher L. Autistic disorder and the endogenous opioid system. Med Hypotheses. 1997;48(5):413–4.PubMedCrossRefGoogle Scholar
  123. 123.
    Lajonchere C, Jones N, Coury DL, Perrin JM. Leadership in health care, research, and quality improvement for children and adolescents with autism spectrum disorders: autism treatment network and autism intervention research network on physical health. Pediatrics. 2012;130(Suppl 2):​S62–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • María Andrea Delgado
    • 1
  • Adriana Fochesato
    • 1
  • Luis Isaías Juncos
    • 1
  • Pascual Ángel Gargiulo
    • 2
  1. 1.Fundación J Robert CadeCórdobaArgentina
  2. 2.Laboratorio de Neurociencias y Psicología Experimental, Área de Farmacología, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, CONICETMendozaArgentina

Personalised recommendations